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Abstract
Patients with advanced cancer often suffer from cachexia, a 
debilitating and complex extreme weight loss syndrome which 
is also associated with shorter survival times. A pragmatic 
randomised controlled trial was conducted to determine whether 
an oral nutritional supplement containing the omega-3 fatty acid 
eicosapentaenoic acid (EPA) was able to improve quality of life and 
survival times of patients with advanced solid tumour cancer in a 
mixed tumour cancer type population.
Keywords: Cancer;  Cachexia; Eicosapentaenoic Acid (EPA); 
Survival.
Patients and Methods
Twenty-seven patients were randomly assigned to receive 2 
cartons daily of either an EPA nutritional supplement or a matched 
supplement (without EPA) for a total period of 8 weeks. Gross 
weight, body composition, appetite, functional status and quality 
of life were assessed (baseline, 4 and 8 weeks) and survival data 
recorded.   Factors regarding compliance, tolerability, as well as 
flavour and serving preferences were also assessed.
Results
Inadequate recruitment of suitable participants together with a 
deteriorating patient population resulted in inconclusive findings. 
However, there were interesting observations: Firstly, in either 
group, consuming between 1.5 and 2 cartons per day of a nutritional 
supplement (regardless of type) over a 4-week period, resulted 
in stabilisation of weight loss with a small, but statistically non-
significant weight gain and secondly, patients in the EPA survived 
up to three times longer than those in the non-EPA arm.  
Conclusion
Lessons learned from conducting this trial may provide guidance 
for further studies that are required to firmly establish whether 
there is a role for EPA nutritional for advanced cancer patients.
Introduction 
Cachexia is a distressing syndrome of severe weight loss and is a 
common manifestation of advanced cancer.   Cachexia is a major 
cause of mortality since cachexic patients usually have a shorter 
survival time compared to other terminally ill cancer patients 
[1, 2]. The definitive treatment of cancer is total removal of the 
causative tumour, but when this is not an option and survival of 
patients is limited, the focus of any intervention turns to the relief 
of symptoms, including cachexia and improving the patient’s 
quality of life. 
Eicosapentaenoic acid (or EPA) is an omega-3 polyunsaturated 
fatty acid which has been associated with a number of reported 
benefits in patients with cancer including stabilising weight loss, 
reducing post-surgery infections and prolongation of survival [3]. 
It has been suggested that since cancer can result in a systemic 
inflammatory response EPA may have a role to play in both the 
modulation of pro-inflammatory cytokines production and the 
mechanisms underlying these effects [4].
The decision to conduct our randomised controlled trial followed 
the completion of a Cochrane systematic review [5] which revealed 
a paucity of well conducted randomised controlled trials (RCTs) to 
adequately determine whether EPA could improve clinical outcomes 
for advanced cancer patients.  On an intention to treat basis, EPA 
two trials reported EPA as either no better than the control arm 
for patients with unresectable pancreatic cancer [6] or worse for 
patients with mixed tumour types where combining EPA with the 
appetite stimulate Megestrol (MA) resulted in a slight inhibitory 
effect of MA on the action of EPA so that it was less effective than 
EPA alone [7]. There was insufficient data to confirm the survival 
advantage seen in a small placebo randomised controlled study of 
60 patients with generalised solid tumour cancer [8].  
Patients And Methods
Full ethical approval was obtained prior to conducting a randomised 
single blind controlled trial over a period of 20 months closing at 
the end of March 2006. Recruitment of patients was actively sought 
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through a number of sources: consultant oncologist, Macmillan 
nurses, palliative care consultant, other hospice staff, dieticians, 
specialist cancer nurses, general practitioners, and district and 
community nursing teams.  Adults (over 18 years old, male or 
female) with advanced solid tumour cancer (with weight loss) were 
recruited in to the study if they had either a histological proven or 
a firm radiological or operative diagnosis of solid tumour cancer, 
defined as either recurrent or metastases or for whom no active 
curative treatment was planned. Patients were included only if they 
had a history of on-going weight loss (5% over previous 3 months 
or more).  Concurrent palliative chemotherapy, radiotherapy 
or taking oral corticosteroids was permitted, but patients were 
excluded if they were already regularly taken one (or more) oral 
fish oil capsules/tablets, taking other appetite stimulants or if, at 
the time of enrolment, they had evidence of gross ascites, jaundice, 
pyrexia, severe anaemia or suffering acute infection. Patients were 
not excluded if they had ankle oedema.  
Intervention: Patients were randomised to receive either an oral 
nutritional supplement containing EPA (Prosure™ supplied from 
Abbott Laboratories) or standard oral nutritional supplement not 
containing EPA (Ensure Plus™ supplied by Abbott Laboratories). 
Both Prosure™ and Ensure Plus™ supplements provided a 
milkshake type food supplement specifically designed for medical 
purposes, but there were some differences between the nutritional 
content of the two supplements.  The Ensure Plus™ (without EPA) 
supplement offered more fat, calories and carbohydrate content 
than the Prosure™ (with EPA) supplement. In contrast, each carton 
of Prosure™ supplement contained more protein with the addition 
of fibre. It was decided to restrict the choices of both the nutritional 
supplements to two of the most popular flavours of Prosure™ 
(banana and vanilla flavours), but if patients expressed a flavour 
preference, arrangements were made for changeover of flavour 
choice to be supplied.  
The decision to provide EPA combined with a protein and energy 
enriched oral nutritional supplement was based on previous 
research findings on patients with unresectable pancreatic cancer 
that suggested that combining EPA with an enriched nutritional 
supplement could result in weight gain rather than just weight 
stabilisation when 2 cartons are consumed daily to provide a 
suggested therapeutic dose of 2.1g EPA [9, 6]. Following an 
extensive search for a suitable EPA nutritional supplement, 
Prosure™ appeared to be the best available source at the time. Costs 
involved prohibited Abbott Laboratories’ direct involvement to 
provide a blinded matched control. Ensure Plus™ was a pragmatic 
alternative choice since it was both the nearest matched control for 
nutritional content and, as part of local practice at the time, often 
recommended as the standard nutritional supplement by clinicians 
for cancer patients with weight loss. This was a single blind trial 
where only the statistician was blinded to the group allocation. 
However, details of the randomisation process were concealed 
from both the lead researcher and patient until after consent and 
full enrolment into the study.
Primary Outcome Measures: The primary outcome measures 
were changes in gross body weight and body composition. The 
same researcher weighed all the patients at each time point using 
portable weighing scales (SECA Model 835). All patients were 
weighed without footwear and wearing light clothing with weight 
recorded in kilograms. Body composition was assessed using 
anthropometric measurements to detect a change in lean body fat. 
Two measurements, mid-arm circumference (MAC) and triceps 
skin fold (TSF) provided two practical measurements to use and are 
particularly suitable for objective measurement in more acutely ill 
patients [10]. These two measurements were combined to provide 
an indirect determinant of mid-arm muscle area (MAMA = [MAC 
(cm) - π X TSF (cm) 2/4π] –10 {corrected for males}.
Secondary Outcome Measures: Additional data collected 
included appetite status, functional status, quality of life status 
each measured at baseline, 4 and 8 weeks and survival.  Appetite 
was assessed using a 7-scale rating score where 0= No Appetite and 
7= Excellent Appetite to provide a measurement of the increase or 
decrease in appetite status for the previous week. Functional status 
was measured using the 5-point WHO Zubrod scale [11] where 
0 = Normal activity and 4 = Unable to get out of bed. Quality of 
life status was measured using the EORTC 30 self-administered 
questionnaire, which includes scales for global health status, quality 
of life, functionality and symptoms. 
Patients recorded daily consumption (i.e., 2 cartons, 1 carton, 
½ carton or none) on specifically designed recording charts. In 
addition, patients were asked to make a note of any side effects 
or new symptoms that they had experienced whilst on the 
supplements. Each side effect or new symptom was recorded 
as one event. Multiple symptoms were recorded as individual 
events with as much information as possible to describe the event. 
CONTENTS PER TETRA CARTON PROSURE* ENSURE PLUS*
TOTAL VOLUME 240mls 240mls
CALORIES 300kCal 360kCal
PROTEIN 16g 13g
FAT
Saturated Fat
EPA
DHA
6.14g
2.93g
1.09g
0.46g
11g
CARBOHYDRATE 44g 50g
FIBRE 3g 0g
MINERALS   (different types)
VITAMINS    (different types)
17
13
15
13
Table 1: Nutritional Values and Contents for Each Supplement
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Finally, information regarding flavour and serving preferences 
were documented to explore in more detail, what factors, both 
positive and negative, might influence the patient’s compliance 
with consuming the nutritional supplement allocated.
Sample Size Calculation
The sample size calculation was based on previously published 
small clinical trials looking at the use of EPA versus placebo in 
pancreatic cachexic patients [12, 13]. Assuming an underlying 
normal model, estimates of the mean weight loss derived from 
these papers, suggested expected values of 2.8-2.9 kg/month with a 
standard deviation of 1.50-1.90 kg/month for a control group. With 
a standard deviation of 1.5 kg/month, a parallel study involving 37 
subjects per arm would be expected to provide a power of 80% in 
detecting a difference of 1 kg/month in mean weight loss between 
two groups when tested at the 5% significance level. This figure was 
rounded up to 40 per group. Allowing for a 20% attrition rate, the 
total number of patients required was 100 participants; 50 in the 
treatment group and 50 in the control group.  
Randamisation Of Participants  
A computer generated randomisation table was created by the 
study statistician (BH) with a copy of the randomisation sequence 
kept in a locked cabinet. Patients were randomised at enrolment in 
permutation blocks of four using a sequential series of numbered 
sealed envelopes containing the computer generated random 
assignments.
Procedure
Patients were invited to take part in the study by means of an 
introductory letter and written information and written informed 
consent obtained. The researcher visited all patients in their home 
with subsequent visits at 4 weeks and 8 weeks. On entry to the study, 
two baseline measurements of nutritional status were carried out: 
the Patient-generated Subjective Global Assessment of Nutritional 
Status questionnaire (or PG-SGA) as well as calculation of the 
patient’s body mass index (or BMI). 
Data Analysis
Data were analysed on an intention to treat basis using SPSS 
(Statistical Package for Social Sciences, Chicago, Illinois, USA 
version 14.5). Differences in mean weight loss were compared 
using a Student’s t test, Quality of Life data compared using the 
Mann-Whitney U test and categorical data compared using Fisher’s 
exact test. Survival rate curves were constructed using the product 
limit (Kaplan Meier) method and comparisons between treatment 
groups made using the Log-rank test. 
Results
A total of fifty-seven participants were identified as eligible to take 
part in the study. (Figure 1) shows the flow of participants through 
the study.
Thirty patients did not take part in the study. Three did not meet 
the inclusion criteria and twenty-seven patients declined to take 
part.  (Table 1) summarises the reasons patients were excluded 
from the study.
REASON givEN FOR NOT TAKiNg PART iN 
STUDy FREQUENCy
Decline in medical condition 6
Changed mind about taking part 11
Prescribed nutritional supplement by GP 1
No reason given 9
Excluded   1 = Not Solid Tumour type
                  1 = Gained Weight
                  1 = Refusal to stop own fish oil 
capsules
3
                              TOTAL 30
Table 2: Patients excluded from the study
The 27 participants recruited into the trial were randomised to one of 
two groups.  Descriptive statistics summarising their demographic 
characteristics and baseline assessments are presented in (Table 
2).   
Figure 1: Study flow chart
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The majority of study participants were male (19 males, 8 females). 
Eighteen patients were classified as being at a localised stage of dis-
ease; two with loco-regional stage and three with disseminated. No 
data on stage of disease were available for four patients. At baseline 
patients had lost an average of approximately 13% of their pre-ill-
ness stable weight. On entry to the study one patient was receiv-
ing palliative radiotherapy and four patients receiving palliative 
chemotherapy. Ten patients received concomitant oral corticoste-
riods with two having used them in the previous 2 weeks. Using 
the (PG-SGA) questionnaire, twenty-four patients were classified 
as moderately malnourished and three as severely malnourished. 
The PG-SGA nutritional management score indicated that twenty-
four patients had a critical need for nutritional or pharmacological 
interventions and in general, other values showed below average 
scores of physical function and global health status. Baseline char-
acteristics of the two study groups were similar.
Withdrawals And Dropouts: Although twenty-seven patients 
(13 intervention and 14 control) were assessed at baseline, only 21 
were available to be assessed at 4 weeks (12 intervention and 9 con-
trol) and 16 patients at eight weeks (9 intervention and 7 control). 
Among the patients who took part in this study a number of minor 
new symptoms as well as side effects were reported (Table 3).  
NUMBER OF PATIENTS
New Symptoms/
side effects
Intervention 
(EPA) Group 
(n=13)
Control 
(without EPA) 
Group (n=14)
*P value
Sense of fullness 
and eats less 7 3  0.120
Vomiting 0 3 0.222
Nausea 2 0 0.222
Constipation 1 1 1.000
Loose stools/
diarrhoea 1 1 1.000
Abdominal Pain 1 0 0.481
Flatulence 0 1 1.000
Metallic Taste 0 1 1.000
Fishy Smell/
Taste 1 0 0.481
Table 4: Reported new symptoms or side effects of supplement
* Fisher’s Exact Test
The most common new symptom reported was that of a sense of 
fullness that usually resulted in patients eating less. This effect was 
mentioned slightly more frequently in the intervention arm than 
the control arm. However, there were no statistically significant 
differences in the number of patients who experienced either new 
symptoms or side effects between the study arms. 
BASELiNE CHARACTERiSTiCS iNTERvENTiON 
(n=13)
CONTROL
(n=14)
Gender (Males: Females) 9M: 4F 10M: 4F
Age: mean (SD) years
Median (range)
73.1 (9.3)
72 (58-87)
65.6 (11.5)
68 (40-77)
Tumour Types
Lung
Mesothelioma
Oesophagus
Pancreas
Prostate
Myeloma
Stomach
8
4
1
8
2
2
1
1
Initial Staging  of Disease:
Local
Loco-regional
Disseminated
Missing Data
11
1
0
1
7
1
3
3
Radiotherapy 1 0
Chemotherapy 1 3
History of Steroids use 7 5
Weight - Mean (SD), kg 56.4 (9.2) 60.7 (10.8)
% weight loss kg from usual weight  
Mean(SD),%
12.9 (4.2) 13.4    (8.6)
Body Mass index – Mean (SD), kg/m2 20.4 (2.3) 21.1  (2.6)
Ankle Oedema 2 1
Anthropometric measurements:  Mean 
(SD)
Mid-arm circumference, cms
Skin fold measurement, mms
Lean Body Mass (adjusted for gender) 
cm2
25.7 (2.8)
12.7 (4.5)
18.0(30.2)
27.0 (2.5)
12.7 (4.0)
14.9(32.2)
PG-SGA  Stage:
Stage B= moderately malnourished
Stage C=severely malnourished
12
1
12
2
Pg SgA Score:
4-8 = Requires Intervention
>9 = Critical Need of Intervention
1
12
2
12
Appetite Status  Median (range)
(0= no appetite to 7= excellent)
3.5  (1-7) 3.2 (2-7)
Zubrod Performance Score  Median 
(range)
(0=Normal to 4=  unable to get out of 
bed)
1.0 (0-2) 1.0 (1-2)
EORTC QLQ-C30  Mean (SD)
Global Health score
High scores= high level of function & 
Quality of Life
48.10 (26.4) 47.62 (15.9)
Table 3: Patient characteristics at baseline by treatment regimen
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Primary and Secondary Outcomes
We failed to find significant differences between the groups for 
gross body weight, body composition, appetite, functional status 
or quality of life between patients taking the EPA supplement 
compared to those taking the non-EPA supplement in this study. 
The observed differences are presented in (table 4) below.
It should be noted that, since we were unable to achieve the target 
sample size, this study lacks statistical power.  Moreover, the 
absence of a statistically significant difference between treatments 
is not evidence of equivalence. 
For this reason, we discuss the findings in order to explore the 
observed changes further.
Exploring the data: Trend towards weight stabilisation and 
improved survival: Exploration of the data was undertaken to 
variable Intervention Group (EPA) Control group
(Without EPA)
Difference 95% Confidence Intervals &
P value
Gross Weight (kg) 0.11 (1.42) 1.25  (4.45) -1.14 (–4.61 to +2.34) *p=0.479
Lean Body Mass (cm2) 4.1 (21.2) 25.3  (32.9) -21.2 (-5.8,44.5)
*p=0.1265
Appetite Status: 3.58 (1.55) 3.54(1.38) -0.04 **p=0.42
Functional Status 1.23(0.60) 1.29(0.47) -0.06 **p=025
Global QoL Status: 48.08 (26.39) 47.62(15.91) -0.46 **p=0.46
Table 5: Change from baseline at four weeks by treatment regimen
Figures written as means with standard deviation unless otherwise stated
*      Independent samples t test
**    Mann Whitney U Test
NB:   Data not shown for 8 weeks measurements due to small numbers of patients involved
see whether there was any underlying trend of weight stabilisation 
and survival data.  Patients in each arm were asked to consume 2 
cartons a day (total 56 cartons) over a four-week period to provide 
(in the Intervention group) a daily EPA dose of 2.2g/day. At week 
4 participants in the intervention arm reported consuming, on 
average, approximately 1 carton per week more (7 over 4 weeks) 
than the control group, although this difference was not statistically 
significant (t = 1.01, p = 0.33). 
In the Intervention group 6 patients either become weight stable 
or increased their weight after consuming 10 or more cartons. 
Maximum weight gain in the Intervention group was seen after 
consumption of 50 or more cartons.  In the Control group, 3 
Figure 2: Relationship between compliance and weight 
differences for both arms at 4 weeks
patients increased their weight after consuming 40 or more cartons. 
Selecting those patients that took 42 or more cartons (to give the 
recommended dose of 1.5 to 2 cartons per day  in the Intervention 
group) and comparing the mean weight gain with the control group 
of similar compliance, showed a trend towards weight gain in both 
arms (Daily: Intervention group: 1.18 cartons SD=1.51; Control 
Group: 2.03 cartons SD=2.56).  However, the numbers involved 
were too small to complete any meaningful significance testing.
Survival data were recorded of each participant with observations 
censored beyond 15th March 2006. Survival curves were constructed 
using the product limit (Kaplan Meier) method and presented in 
(Figure 3). Treatments were compared using the Log-rank test.
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Although patients in the intervention arm survived three times 
longer on average than those in the control arm (median 179 days 
versus 55 days), the difference failed to reach statistical significance 
(p = 0.09).
Flavour and serving preferences: Both However, in the control 
arm at the end of the 8 weeks study, the majority of the patients 
(6 out of 7 patients) said that they would like to continue to use 
the nutritional supplement and in particular would like to try 
other flavours.  In the intervention arm half of the patients (4 out 8 
patients, data missing for 1 patient) expressed a desire to continue 
using the supplement despite the lack of flavour choice. The 
majority of patients in both arms preferred to take the nutritional 
supplement chilled from the refrigerator (Intervention Arm: n=11, 
Control Arm: n=7) and straight from the tetra carton (intervention 
arm: n=8, control arm: n= 7). None of the patients in either arm 
had tried any of the recipe sheets given, but one patient in the 
intervention arm added ice-cream sauce to the vanilla to disguise 
the taste and used the banana flavoured nutritional supplement as 
pouring custard over fruit. Nutritional supplements were generally 
well tolerated. The majority of patients in both arms did not have a 
particular taste preference although in the intervention arm banana 
flavour was a more popular flavour than vanilla. Some patients (in 
both arms) said that, by the end of the study period, they were 
“tired of the flavours” offered.  
Discussion 
The key findings from this study were that there were no significant 
differences in either the primary or secondary outcomes measured 
after the administration of the Intervention (Prosure™ an EPA 
nutritional supplementation) compared to that of the control 
group (Ensure Plus™ a nutritional supplement without the addition 
of EPA). This study was, however, underpowered due to poor 
recruitment and higher than expected attrition rates resulted in too 
few patients being available for assessment. It cannot, therefore, be 
concluded that EPA supplements are ineffectual. 
However in both groups, consuming between 1.5 and 2 cartons 
per day over the 4-week period resulted in a corresponding weight 
gain. This suggests that high-energy protein rich nutritional 
supplements (with or without EPA) may provide additional support 
for advanced patients with mixed tumour cancer types, but further 
research is necessary to establish which type (and if this matters at 
all) of nutritional supplement is more useful.  
In line with previous findings [8], patients taking EPA in this study 
survived longer on average, although our findings failed to reach 
statistical significance. For those patients who prefer not to pursue 
palliative treatment, it is possible that EPA could provide an acceptable 
alternative or adjunct to chemotherapy regimes, but further studies 
are still required to see whether it can provide a realistic option that 
is acceptable to the patient and meets their needs and expectations. 
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(Key:  arm 1= control arm, arm 2 = intervention arm)  (Log Rank Test, p=0.09) 
Figure 3: Overall Survival by Treatment Group
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Limitations of the study and future research: There were a 
number of limitations in the execution of this study. These included 
insufficient recruitment, high attrition rates and poor compliance. 
With a small sample size the study findings are at risk of small 
imbalances in baseline characteristics, and so could have benefitted 
from stratification of randomisation. However there is no one clear 
predictor for weight loss in people with cancer cachexia [14] and 
so until more is known about the aetiology of the condition it is 
difficult to identify suitable factors for stratification.
Despite the use of a comprehensive recruitment strategy we were 
unable to accrue sufficient patients into the study.  There are a 
number of possible explanations for poor recruitment. Firstly it is 
possible that low referral rates were due to insufficient identification 
of potential participants. At the time of the study, patients were 
not routinely weighed, referred for dietary assessment, advice 
or supplementation  In a separate qualitative study [15] we have 
since explored  management of patients with advanced cancer 
and weight loss through audio-taped semi-structured interviews 
with fourteen  nurses (both hospital and community settings). 
Analysis of the findings revealed that many nurses interviewed did 
not routinely provide early identification and assessment of weight 
loss, nor did they continue to monitor the patient’s nutritional 
status. In addition, many of the nurses were reluctant to initiate 
conversations with cancer patients about weight loss, but instead 
waited for patients and relatives to raise their concerns.
 It is also possible that potential health care referrers acted as “gate-
keepers” to suitable patients for the study. All potential health care 
referrers were contacted periodically in order to maintain the profile 
of the trial, but it was difficult to maintain a high level of contact. 
Highest recruitment figures were achieved with those healthcare 
professionals who were actively involved in project supervision as 
part of the Trial Steering Committee.  
While initially many health care professionals showed interest 
in referring patients, over time further discussions suggested 
some healthcare professionals were sceptical about the benefits of 
entering patients in to the study. Views were expressed about the 
lack of effect of any nutritional supplementation, regardless of type; 
belief that patients who are already very ill would be burdened 
by a commitment to consume large quantities of nutritional 
supplementation as well as concerns about the possibility of 
additional side effects.  
Another problem was the higher than expected attrition rate. The 
target for recruitment was 100 to allow for an anticipated attrition 
rate of 5-10%. Recruitment of patients into the study proved more 
difficult than anticipated and we were only able to assess eligibility 
of just over half of the patients we required to take part in the study 
(N=57). Once randomised into the study, the number of patient 
withdrawals and dropouts were higher than anticipated (41% in the 
Intervention Arm and 50% in the Control Arm). In the majority of 
cases, this was due to rapid decline with patients either dying or being 
too ill to continue. We adopted a number of strategies to address 
potential problems of compliance. Regular telephone contact with 
home visits by the same researcher throughout the study enabled a 
good patient/researcher rapport and was felt to enhance compliance 
(and minimise attrition rates) in both arms of the study. In addition 
all supplements were supplied to the home and patients were able 
to change flavour choices delivered to the home if they wished to do 
so. Despite our efforts, many patients (in both arms of the study) did 
not regularly consume the nutritional supplementation. This may 
be due to a number of factors. Although both supplementations 
were generally well tolerated it is reasonable to anticipate that 
patients may take more of the nutritional supplement if they feel it 
is working or less if it is not working. However, since consumption 
was fairly consistent over time it is more likely that this reflects 
the deteriorating condition of the patient’s ability to tolerate the 
nutritional supplement allocated. Typically patients were initially 
enthusiastic to try nutritional supplements, but poor appetite 
and early satiety resulted in some patients finding it difficult to fit 
meals around taking two supplements. It may be that taking the 
nutritional supplement further suppressed appetite and usual food 
intake. In this case, the nutritional supplement would be replacing 
the energy generally supplied by usual food intake and failing to 
provide the substantial increase in total energy intake required. 
Although the results from our Cochrane systematic review [5] 
suggest that combining the appetite stimulant, Megestrol Acetate 
with EPA may result in a slight inhibitory effect, it is possible other 
appetite stimulants, such as corticosteroids, may prove more useful 
to use in conjunction with nutritional supplementation use. Future 
trialists might also consider collecting additional information to 
assess impact of the timing of supplement consumption on both 
appetite and food intake or whether patients were using nutritional 
supplements as a replacement for other food. 
Conclusion
Cancer cachexia remains under-investigated, despite significant 
morbidity and mortality. The role of an EPA nutritional supplement 
as an effective intervention remains uncertain. There is a need for 
further investigation, but the challenge will be identifying and 
recruiting suitable cancer patients into such a study. 
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